Table 3.

Efficacy Outcome by Prior-Aspirin Subgroup.

		Ticagrelor 90 mg bd (n=6589)			Aspirin 100 mg OD (n=6610)
Efficacy outcome	Prior aspirin*	n	Patients with events (%)	KM%†	n	Patients with events (%)	KM%†	HR (95% CI)	P Value	P value interaction‡
Composite of stroke/MI/death	Yes	2130	138 (6.5)	6.5	2102	177 (8.4)	8.3	0.76 (0.61–0.95)	0.02	0.10
	No	4459	304 (6.8)	6.9	4508	320 (7.1)	7.1	0.96 (0.82–1.12)	0.59
Prior-aspirin therapy,* by start day	Chronic treatment§	890	58 (6.5)	6.6	841	66 (7.8)	7.4	0.82 (0.58–1.17)	0.27	0.58
	Acute treatment|	1240	80 (6.5)	6.5	1261	111 (8.8)	8.8	0.72 (0.54–0.97)	0.03
Prior-aspirin therapy,* by dose	Dose >150 mg	792	51 (6.4)	6.5	796	64 (8.0)	8.0	0.80 (0.55–1.15)	0.23	0.74
	Dose ≤150 mg	1338	87 (6.5)	6.6	1306	113 (8.7)	8.4	0.74 (0.56–0.98)	0.03
Stroke	Yes	2130	126 (5.9)	6.0	2102	154 (7.3)	7.2	0.80 (0.63–1.01)	0.06	0.41
	No	4459	264 (5.9)	6.0	4508	296 (6.6)	6.6	0.90 (0.76–1.06)	0.21
MI	Yes	2130	8 (0.4)	0.4	2102	10 (0.5)	0.5	0.79 (0.31–1.99)	0.61	0.26
	No	4459	17 (0.4)	0.4	4508	11 (0.2)	0.3	1.57 (0.73–3.35)	0.25
Death	Yes	2130	16 (0.8)	0.8	2102	25 (1.2)	1.2	0.63 (0.34–1.18)	0.15	0.02
	No	4459	52 (1.2)	1.2	4508	33 (0.7)	0.7	1.60 (1.03–2.47)	0.04
Ischemic stroke	Yes	2130	123 (5.8)	5.8	2102	153 (7.3)	7.1	0.78 (0.62–0.99)	0.04	0.29
	No	4459	262 (5.9)	5.9	4508	288 (6.4)	6.4	0.92 (0.78–1.08)	0.31

bd, twice daily; MI, myocardial infarction; OD, once daily

^*Patients in the prior-aspirin subgroup had received aspirin within 7 days before randomization

^†Kaplan-Meier %; the event rate at 90 days

^‡Interaction between treatment assignment and prior aspirin indicator was evaluated by including terms for treatment, prior-aspirin indicator, and treatment-by-prior-aspirin indicator interaction in the Cox model (P<0.05 was considered statistically significant)

^§Start of treatment occurring earlier than the day before randomization

^|Start of treatment occurring the day before or the same day as randomization